BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15910011)

  • 1. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant.
    Bergman AJ; Marbury T; Fosbinder T; Swan S; Hickey L; Bradstreet TE; Busillo J; Petty KJ; Aiyer KJ; Constanzer M; Huskey SE; Majumdar A
    Clin Pharmacokinet; 2005; 44(6):637-47. PubMed ID: 15910011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
    Lasseter KC; Gambale J; Jin B; Bergman A; Constanzer M; Dru J; Han TH; Majumdar A; Evans JK; Murphy MG
    J Clin Pharmacol; 2007 Jul; 47(7):834-40. PubMed ID: 17525168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
    Blum RA; Majumdar A; McCrea J; Busillo J; Orlowski LH; Panebianco D; Hesney M; Petty KJ; Goldberg MR; Murphy MG; Gottesdiener KM; Hustad CM; Lates C; Kraft WK; Van Buren S; Waldman SA; Greenberg HE
    Clin Ther; 2003 May; 25(5):1407-19. PubMed ID: 12867217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
    Shah AK; Hunt TL; Gallagher SC; Cullen MT
    Curr Med Res Opin; 2005 Apr; 21(4):595-601. PubMed ID: 15899109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
    Ottoboni T; Keller MR; Cravets M; Clendeninn N; Quart B
    Drug Des Devel Ther; 2018; 12():429-435. PubMed ID: 29535504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
    Stangier J; Rathgen K; Stähle H; Mazur D
    Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.
    Majumdar AK; Howard L; Goldberg MR; Hickey L; Constanzer M; Rothenberg PL; Crumley TM; Panebianco D; Bradstreet TE; Bergman AJ; Waldman SA; Greenberg HE; Butler K; Knops A; De Lepeleire I; Michiels N; Petty KJ
    J Clin Pharmacol; 2006 Mar; 46(3):291-300. PubMed ID: 16490805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.
    Kasserra C; Sansone-Parsons A; Keung A; Tetteh E; Assaf M; O'Mara E; Marbury T
    Clin Pharmacokinet; 2010 Jun; 49(6):397-406. PubMed ID: 20481650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic renal failure on the pharmacokinetics of ruboxistaurin and its active metabolite 338522.
    Wise S; Yuen E; Chan C; Poo YK; Teng L; Lau T; Voelker J
    Clin Pharmacokinet; 2006; 45(3):297-303. PubMed ID: 16509761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
    Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
    Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.
    Takahashi T; Nakamura Y; Tsuya A; Murakami H; Endo M; Yamamoto N
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):653-9. PubMed ID: 21125277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
    Hsyu PH; Pignataro DS; Matschke K
    Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
    Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
    Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
    Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
    Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aprepitant on the pharmacokinetics of intravenous midazolam.
    Majumdar AK; Yan KX; Selverian DV; Barlas S; Constanzer M; Dru J; McCrea JB; Ahmed T; Frick GS; Kraft WK; Petty KJ; Greenberg HE
    J Clin Pharmacol; 2007 Jun; 47(6):744-50. PubMed ID: 17463213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib.
    Gottesdiener K; Agrawal N; Porras A; Wong P; Rogers JD; Gertz BJ; Redfern JS; Marbury T
    Am J Ther; 2003; 10(4):252-8. PubMed ID: 12845388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.